全文获取类型
收费全文 | 1150篇 |
免费 | 96篇 |
国内免费 | 13篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 35篇 |
妇产科学 | 8篇 |
基础医学 | 95篇 |
口腔科学 | 18篇 |
临床医学 | 189篇 |
内科学 | 405篇 |
皮肤病学 | 5篇 |
神经病学 | 17篇 |
特种医学 | 191篇 |
外科学 | 64篇 |
综合类 | 66篇 |
预防医学 | 38篇 |
眼科学 | 13篇 |
药学 | 54篇 |
1篇 | |
肿瘤学 | 56篇 |
出版年
2022年 | 6篇 |
2021年 | 18篇 |
2020年 | 13篇 |
2019年 | 13篇 |
2018年 | 25篇 |
2017年 | 13篇 |
2016年 | 16篇 |
2015年 | 30篇 |
2014年 | 19篇 |
2013年 | 31篇 |
2012年 | 57篇 |
2011年 | 55篇 |
2010年 | 25篇 |
2009年 | 30篇 |
2008年 | 41篇 |
2007年 | 49篇 |
2006年 | 46篇 |
2005年 | 53篇 |
2004年 | 40篇 |
2003年 | 42篇 |
2002年 | 32篇 |
2001年 | 35篇 |
2000年 | 25篇 |
1999年 | 28篇 |
1998年 | 27篇 |
1997年 | 30篇 |
1996年 | 21篇 |
1995年 | 28篇 |
1994年 | 22篇 |
1993年 | 35篇 |
1992年 | 18篇 |
1991年 | 14篇 |
1990年 | 21篇 |
1989年 | 32篇 |
1988年 | 34篇 |
1987年 | 44篇 |
1986年 | 36篇 |
1985年 | 31篇 |
1984年 | 16篇 |
1983年 | 16篇 |
1982年 | 10篇 |
1981年 | 15篇 |
1980年 | 14篇 |
1979年 | 3篇 |
1978年 | 7篇 |
1977年 | 7篇 |
1975年 | 6篇 |
1973年 | 3篇 |
1970年 | 3篇 |
1964年 | 3篇 |
排序方式: 共有1259条查询结果,搜索用时 0 毫秒
1.
2.
3.
4.
Ten thrombocytopenic patients (platelets < 10–24 × 10(9)/L) who were refractory to platelet transfusion were investigated for their responsiveness to staphylococcal protein A column therapy. Nine patients had previously been treated with steroids, intravenous immune globulin, and/or other forms of immunosuppressive therapy without improvement in their transfusion response. All patients were receiving multiple platelet transfusions without achieving 1-hour corrected count increments (CCIs) > or = 7500. Eight patients had antibodies that reacted with platelets and were directed against HLA class I antigens, ABO antigens, and/or platelet-specific alloantigens. Plasma (500-2000 mL) from each patient was passed over a protein A silica gel column and then returned to the patient. Patients received from 1 to 14 treatments. A positive response to protein A therapy was defined as at least a doubling of the pretreatment platelet count and/or two successive 10- to 120-minute posttransfusion CCIs > or = 7500. Following plasma treatments, 6 of 10 patients responded with daily platelet counts that averaged 48 +/− 11 × 10(9) per L as compared with counts of 16 +/− 7 × 10(9) per L (p < 0.0005) before treatment. Posttransfusion CCI values determined in four of these patients averaged 2480 +/− 810 and 10,010 +/− 3540 (p < 0.005) before and after treatment, respectively. In contrast, among the four unresponsive patients, platelet counts averaged 10 +/− 9 and 13 +/− 10 × 10(9) per L (p = NS), respectively, while posttransfusion CCIs were 700 +/− 1410 and 1520 +/− 2460 (p = NS), respectively.(ABSTRACT TRUNCATED AT 250 WORDS) 相似文献
5.
Genetically-determined interaction between propafenone and low dose quinidine: role of active metabolites in modulating net drug effect. 总被引:2,自引:2,他引:0
下载免费PDF全文
![点击此处可从《British journal of clinical pharmacology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
C Funck-Brentano H K Kroemer H Pavlou R L Woosley D M Roden 《British journal of clinical pharmacology》1989,27(4):435-444
1. Quinidine is a potent inhibitor of the genetically-determined debrisoquine 4-hydroxylation. Oxidation reactions of several other drugs, including the 5-hydroxylation of the new antiarrhythmic drug propafenone, depend on the isozyme responsible for debrisoquine 4-hydroxylation. 2. The effect of quinidine on the debrisoquine phenotype-dependent 5-hydroxylation and the pharmacological activity of propafenone was studied in seven 'extensive' metabolizers and two 'poor' metabolizers of the drug receiving propafenone for the treatment of ventricular arrhythmias. 3. In patients with the extensive metabolizer phenotype, quinidine increased mean steady-state plasma propafenone concentrations more than two fold, from 408 +/- 351 (mean +/- s.d.) to 1096 +/- 644 ng ml-1 (P less than 0.001), decreased 5-hydroxypropafenone concentrations from 242 +/- 196 to 125 +/- 97 ng ml-1 (P less than 0.02) and reduced propafenone oral clearance by 58 +/- 23%. 4. Despite these changes in plasma concentrations, electrocardiographic intervals and arrhythmia frequency were unaltered by quinidine coadministration, indicating that 5-hydroxypropafenone contributes to the pharmacologic effects of propafenone therapy in extensive metabolizers. 5. In contrasts, plasma concentrations of propafenone and 5-hydroxypropafenone remained unchanged in the two patients with the poor metabolizer phenotype. 6. Biotransformation of substrates for the debrisoquine pathway can be markedly perturbed by even low doses of quinidine; interindividual variability in drug interactions may have a genetic component. 相似文献
6.
Cholelithiasis: a serious complication after total gastrectomy 总被引:7,自引:0,他引:7
P Hauters A de Neve de Roden A Pourbaix F Aupaix P Coumans G Therasse 《The British journal of surgery》1988,75(9):899-900
To establish the incidence of cholelithiasis after total gastrectomy, patients operated on between 1979 and 1985 were reviewed. The study group consisted of 30 patients, all free of gallstones at the time of their gastrectomy. The median age of the patients was 56 years, the average follow-up 40 months. Cholelithiasis developed in 47 per cent of patients (14/30) and always within 2 years of total gastrectomy. The incidence of cholelithiasis was not related significantly to the sex or age of the patients. Morbidity from cholelithiasis was not negligible. Three of the fourteen patients presenting with gallstones required medical treatment in hospital and later came to cholecystectomy because of specific biliary symptoms. Cholelithiasis appears to be a significant complication after total gastrectomy. It may be related to the vagotomy which is performed at the time of gastrectomy. 相似文献
7.
8.
9.
10.
B. J. Young R. O’Regan F. Kinsella A. Benedict-Smith M. McDermott M. Hillery L. M. T. Collum M. Hickey-Dwyer P. Mullaney J. Blake M. Hope-Ross S. Travers D. Mooney P. S. Phelan P. E. Cleary D. F. P. Larkin D. Roden P. Eustace H. N. O’Donoghue J. D. McAdoo J. G. Madden J. P. Burke M. O’Keefe R. Bowell M. O’Sullivan P. T. McLister D. J. Wilson J. Walsh 《Irish journal of medical science》1988,157(3):91-94